Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory Metastatic Colorectal Cancer

ABSTRACT: Interventions: Arm A:tislelizumab combined with cetuximab and irinotecan Primary outcome(s): Overall response rate (ORR) Study Design: Single arm

DISEASE(S): Colorectal Cancer

PROVIDER: 2696054 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR